NEW YORK (GenomeWeb News) – Analysts today upped their price targets on Affymetrix's stock, after the firm posted revenues and net income that surpassed analysts' consensus estimate.

After the close of the market yesterday, Affy reported total second-quarter revenue of $81.6 million, compared to $86.9 million in the comparable period of 2008. Though the revenues declined year over year, the results easily beat analysts' consensus estimates on both the top and bottom lines.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.